Home > Riviste > Minerva Medica > Fascicoli precedenti > Articles online first > Minerva Medica 2021 Mar 25

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

 

Minerva Medica 2021 Mar 25

DOI: 10.23736/S0026-4806.21.07124-X

Copyright © 2021 EDIZIONI MINERVA MEDICA

lingua: Inglese

Comparison of serum tumor markers combined with dual-source CT in the diagnosis of lung cancer

Yuqing SHAN 1, Xiangyuan YIN 1, Na ZHAO 1, Jie WANG 2, Shouxiang YANG 1

1 Department of Imaging, People’s Hospital of Rizhao, Rizhao, China; 2 Department of Imaging, Lanshan People’s Hospital of Rizhao, Rizhao, China


PDF


BACKGROUND: The purpose of this study is to explore the clinical value of serum tumor markers combined with dual-source CT scanning in the diagnosis of lung cancer.
METHODS: 102 patients with lung cancer (malignant tumor group), 50 patients with benign lesions (benign control group) and 50 healthy patients (normal control group) were selected as the research objects. The levels of serum carcinoembryonic antigen (CEA), cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) and gastrin releasing peptide precursor 31-98 (Pro-GRP31-98) were detected using the electrochemiluminescence and enzyme-linked immunoassay in three groups of people. Simultaneously, Siemens' second-generation dual-source CT is used to scan the lungs of patients with lung cancer and benign lesions. Retrospective statistical analysis is utilized to explore the clinical value of serum tumor markers combined with dualsource CT examination in the diagnosis of lung cancer.
RESULTS: The levels of serum CEA, CYFRA21-1 and Pro-GRP31-98 in lung cancer patients were significantly higher than those in the benign control group and normal control group, and the difference was statistically significant (P<0.01). There was no statistical difference between the benign control group and the normal control group (P>0.05). The levels of serum CEA, CYFRA21-1, Pro-GRP31-98 had no significant correlation with the age, sex, and tumor site of lung cancer patients (P>0.05). However, the levels of serum CEA, CYFRA21-1, Pro-GRP31-98 have an obvious correlation with tumor size, clinical stage, histological type, combined pleural effusion, recurrence and metastasis after treatment (P<0.05). CT scans of 102 lung cancer patients showed 35 cases of central type, 67 cases of peripheral type, 71 cases with tumor diameter >5cm, 31 cases of ≤5cm and 67 cases of lymph node metastasis. The sensitivities of CEA, CYFRA21-1, Pro-GRP31-98, and dual-source CT in the diagnosis of lung cancer were 64.70%, 60.11%, 56.86% and 77.45%, and the accuracy was 75.00%, 72.37%, 69.74% and 82.89%, respectively. Compared with a single examination, the sensitivity and accuracy of combined examination for the diagnosis of lung cancer were significantly improved, which were 95.10% and 92.76%, respectively.
CONCLUSIONS: Joint examinations can effectively improve the rate of lung cancer diagnosis.


KEY WORDS: Lung cancer; Tumor markers; Serology; Dual-source CT; Joint examination

inizio pagina